This is an automatically translated article.
Albumin is a protein in human plasma and plays a variety of roles. Patients with deficiency or some specific diseases that need to supplement Albumin can take Zenalb 4.5. So what does Zenalb do?
1. What is Zenalb 4.5?
Each 50mL bottle of Zenalb 4.5 solution includes the following ingredients:
Main active ingredients: Human Albumin 2.25g; Excipients: Sodium 5-8mmol, Chloride 5-8 mmol, Sodium N-Octanoate 0.2-0.5 mmol, Potassium < 0.1125mmol, Citrate < 0.005 mmol and Aluminum < 10pg.
2. What does Zenalb do?
What does Zenalb do? Human albumin accounts for more than half of the total plasma protein and about 10% of the total protein synthesis in the liver. Albumin plays an important role in maintaining volumetric pressure and in transporting substances in the body. Therefore, Zenalb 4.5 helps to stabilize blood volume, while supporting the transport of hormones, enzymes, drugs and toxins in the blood.
3. Indications and contraindications of Zenalb 4.5
3.1. Indications Zenalb 4.5 is indicated for patients with pathologies requiring restoration and maintenance of blood volume, provided colloidal solutions can be used. Choosing Zenalb 4.5 over synthetic colloidal solutions depends on the patient's clinical condition and the recommendations of the medical professional.
3.2. Contraindications The use of Zenalb 4.5 is contraindicated in patients with a history of hypersensitivity to Albumin supplements or to the active ingredients contained in the drug.
4. Dosage, how to use Zenalb 4.5
The concentration of the albumin preparation with dosage and infusion rate is tailored to individual patient needs and Zenalb 4.5 is no exception. The dose of Zenalb 4.5 depends on the patient's weight, the severity of the injury or disease, and the amount of fluid/protein lost or lost.
Volume determination and plasma albumin testing should be performed to determine the most appropriate dose of Zenalb 4.5.
During the Zenalb 4.5 infusion, the patient should be regularly monitored for the following hemodynamic indicators:
Arterial blood pressure; Heartbeat ; Central venous pressure; Pulmonary arterial pressure; Amount of urine; Concentration of blood electrolytes, hematocrit index and blood hemoglobin concentration. Zenalb 4.5 is similar to other Albumin preparations used by direct intravenous infusion. Zenalb 4.5 infusion rate is adjusted according to each patient and doctor's prescription. During plasma exchange, the rate of infusion of Zenalb 4.5 should be adjusted according to the rate of drug elimination.
5. Warnings and Precautions for Zenalb 4.5
Discontinue Zenalb 4.5 infusion immediately if the patient develops symptoms of an allergic or anaphylactoid reaction. Patients with anaphylaxis should receive standard treatment.
Use caution when administering Zenalb 4.5 in cases of hypervolemia, where its consequences or hemodilution may pose a particular risk to the patient. For example:
Patient with decompensated heart failure; Pulmonary hypertension; Esophageal varices; Pulmonary edema; Visceral bleeding; Severe anemia; Urinary retention due to renal and post-renal causes. During the Zenalb 4.5 infusion process, it is necessary to control the patient's electrolyte levels and, if there is an abnormality, immediate therapy should be instituted to restore and maintain electrolyte balance.
Zenalb 4.5 solution must not be diluted with distilled water for injection, as it may cause hemolysis in the patient.
If the blood volume change is too great to occur with Zenalb 4.5, the patient should be monitored for coagulation and red blood cell ratio. At the same time, the patient should be closely monitored to ensure the balance of other blood components such as clotting factors, electrolytes, platelets and red blood cells).
Hypervolemia may occur if the dose and infusion rate of Zenalb 4.5 are not adjusted for the patient's circulatory status. Stop the Zenalb 4.5 infusion at the first clinical symptoms of cardiovascular volume overload (eg, headache, dyspnoea, jugular venous congestion), or hypertension or venous hypertension. central, pulmonary edema.
Standard measures for the prevention of infections caused by the use of human blood or plasma products, including donor selection, screening for infectious factors from donated blood, and substances during production to inactivate or remove the virus. However, when using products from human blood or plasma (such as Zenalb 4.5 ) the possibility of infection with infectious agents cannot be completely excluded.
Vaccination against hepatitis A and hepatitis B should be considered in patients regularly taking human plasma-derived Albumin supplements such as Zenalb 4.5.
To date, no specific interactions of Human Albumin with other drugs have been reported.
Safety when using Zenalb 4.5 in pregnant women has not been established by clinical trials. However, clinical experience shows that the use of Albumin does not have any adverse effects on pregnancy, or on the health of the fetus or newborn. There are no human studies on the effects of Zenalb 4.5 on fertility. Animal studies are insufficient to assess the safety of Zenalb 4.5 for fertility, embryonic or fetal development, or postnatal development.
6. Zenalb 4.5 . Unwanted Effects
Undesirable effects of Zenalb 4.5 may occur as follows:
Mild adverse reactions such as skin redness, urticaria, fever and nausea have rarely occurred in patients receiving Zenalb 4.5. These adverse reactions usually resolve rapidly when the infusion rate of Zenalb 4.5 is slowed down or when the drug is discontinued. Very rarely, severe reactions such as anaphylaxis due to Zenalb 4.5 have occurred. In this case, the patient should immediately discontinue the Zenalb 4.5 infusion and institute appropriate emergency measures. Post-marketing experience with Zenalb 4.5 has shown that some undesirable effects have been spontaneously reported, including shivering, increased blood pressure, hypotension, cold feeling, tachycardia, chills, and spasms. bronchi, shortness of breath, angina, wheezing and dizziness. Patients should inform the doctor about the undesirable effects encountered when taking Zenalb 4.5. Zenalb 4.5 contains the main ingredient Albumin, which is a protein found in human plasma. Zenalb 4.5 is indicated for patients with pathological conditions that require restoration and maintenance of blood volume provided that colloidal solutions can be used.
Follow Vinmec International General Hospital website to get more health, nutrition and beauty information to protect the health of yourself and your loved ones in your family.
Please dial HOTLINE for more information or register for an appointment HERE. Download MyVinmec app to make appointments faster and to manage your bookings easily.
